APT™ T3X on the COVID-19 Contamination Rate

COVID-19 Clinical Trial

Official title:

Use of APT™ T3X to Decrease the COVID-19 Contamination Rate in Humans

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04716426
• Other study ID #: 4.485.847
• Status: Completed
• Phase: N/A
• Start date: January 28, 2021
• Est. completion date: March 25, 2021

Study information

• Verified date: April 2021
• Source: University of Nove de Julho
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The new coronavirus 2019 (COVID-19) was declared a pandemic by the World Health Organization (WHO), due to the alarming levels of spread, severity and inaction. Dealing with COVID-19 must be done on different fronts, such as mitigation, treatment and prevention. Therefore, strategies and therapies that can help reduce the COVID-19 rate of contamination are still important alternatives at this time of the pandemic. The Advanced Penetration Technology™ (APT™) is intellectual property owned by Patient Focused Tele-Health, LLC, a Rockwall, Texas based company. The company's focus is improving over-the-counter (OTC) topical formulations, allowing consumers better therapeutic outcomes with non-prescription medications. The Advanced Penetration Technology™ (APT™) is a patent-pending, proprietary transdermal dual carrier formulation. This formulation provides improved dermal penetration and efficacy of topical API's. Additionally, the APT™ imparts both a mechanical and biochemical effect on the microbe/fungal cell walls providing a highly effective method of destruction of microbes. These unique properties impart the broad spectrum anti-viral capability to the APT™ Tetracycline 3% formulation, breaking barriers in pharmacology and virology. The topical formulation APT™ Tetracycline 3% formulation (APT ™ T3X), is a FDA registered, Non-Prescription product. This formulation is used in an off label manner as an intranasal application for prevention of COVID-19 and other viruses. The APT™ T3X as a topical application will penetrate through and into the mucus layer and deeper. This barrier of coverage will provide a mitigation effect to decrease the viral load of exposure and infection. The efficacy of APT™ T3X is due to disrupting the lipid envelope in seconds, hence neutralizing the virus. Previous tests were performed with APT™ T3X and the results found were promising. However, these tests were performed only in vitro and clinical studies demonstrating the ability of the APT™ T3X to decrease viral exposure and contamination by COVID-19 are necessary to confirm the possible prophylactic effect, allowing the formulation to be widely distributed to the general population. Therefore, the aim of this project is to evaluate the efficacy of the APT™ T3X compared to placebo to decrease COVID-19 contamination rate in humans.

Description:

To achieve the proposed objective it will be performed a randomized, triple blind, placebo-controlled trial. The volunteers will be randomly allocated to two intervention groups: APT™ T3X or placebo. The volunteers will be blinded to the treatment received. One hundred volunteers will be recruited for the study (50 volunteers per group). As this is a preliminary study, the number of volunteers was determined by a convenience sample. The volunteers randomly allocated to the two groups will be instructed to use the APT™ T3X or placebo, once a day, every day for 21 days (except health professionals that will be instructed to use APT™ T3X or placebo twice a day, every day for 21 days). All data will be collected by a blinded assessor. The investigators will analyze: 1. COVID-19 contamination rate. 2. Presence of adverse events. 3. Number of adverse events. 4. Frequency of adverse events. 5. Other virus or bacteria contamination rate. Statistical analysis: The results obtained will first be tested for normality using the Kolmogorov-Smirnov test. The chi-square test or Fisher's exact test for two independent proportions will be used in the statistical analysis of the primary outcome of this study, the COVID-19 contamination rate and for the secondary outcomes: presence of adverse events and other virus or bacteria contamination rate. For the other secondary outcomes, the number of adverse events and frequency of adverse events, the Wilcoxon test will be used if this outcome does not present a normal distribution. If this outcome presents a normal distribution, the two-tailed, unpaired t test will be used. The level of significance used will be 5% (p <0.05).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: March 25, 2021
• Est. primary completion date: March 25, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• good general health (without serious health problems);
• tested negative, by means of immunoglobulin (Ig) G and IgM serology tests and chain real-time polymerase chain reaction (RT-PCR), for COVID-19.

Exclusion Criteria:

• previous immunization against COVID-19;
• allergy to tetracycline hydrochloride;
• diagnosis of Lyme disease;
• immunocompromised;
• share housing with someone diagnosed with COVID-19 at the time of the baseline evaluation;
• serious illnesses, such as cancer, kidney failure, decompensated cardiorespiratory and metabolic diseases, etc.

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• Tetracycline hydrochloride 3%
Proprietary formulation composed of FDA approved inactive ingredients and the active pharmaceutical ingredient tetracycline hydrochloride.
• Placebo
Formulation composed of FDA approved inactive ingredients.

Locations

Country	Name	City	State
Brazil	Santa Casa de Misericórdia de Porto Alegre	Porto Alegre	Rio Grande Do Sul

Sponsors (2)

Lead Sponsor	Collaborator
University of Nove de Julho	Santa Casa de Misericórdia de Porto Alegre

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	COVID-19 Contamination Rate.	Rate of how many people were infected with COVID-19 over the course of the study in each group.	22 days after randomization.
Secondary	Number of Participants With Adverse Events	Number of participants who presented adverse events.	22 days after randomization.
Secondary	Average Number of Adverse Events	Average number of adverse events over the course of the study.	22 days after randomization.
Secondary	Days Over Which an Adverse Event Was Reported	Average days over which an adverse event was reported.	22 days after randomization.
Secondary	Other Virus or Bacteria Contamination Rate.	Rate of how many people were infected with influenza or pneumonia over the course of the study in each group.	22 days after randomization.